Background and Objectives: Analysis of dysfibrinogens has provided useful
Introduction
During fibrin polymerization, thrombin cleaves fibrinogen, releasing fibrinopeptides A (FpA) and B (FpB) from the N-termini of the Aα and Bβ chains, respectively, and converting fibrinogen to fibrin monomers. Fibrin monomers polymerize spontaneously through a calcium-dependent, two-step process. The first of these steps begins with the release of FpA. This exposes the "A" site in the E domain, which interacts with the "a" site in the D domain of a neighboring molecule (the socalled D:E association), leading to the formation of half-staggered, double-stranded twisting protofibrils [1, 2] . Subsequently, the release of FpB exposes the "B" site, which likely interacts with the "b" site in the D domain of another molecule to promote lateral aggregation of the protofibrils [3] . The final product is a complex, branching network of fibers. There is a constitutive self-association site in the γ-chain of each D domain that participates in the interface of two abutted D domains in the same strand of protofibrils (the so-called D:D association), independently of the D:E association [4, 5] .
Analysis of dysfibrinogens has provided useful information aiding our understanding of the above-mentioned molecular events, which promote thrombincatalyzed polymerization [6] [7] [8] . The D:D association has been reported to be essential for end-to-end association of the protofibrils and to be an important determinant of the ultimate network structure of the fibrin clot [4, 5] . In support of this, γArg275 mutations are the second most common mutations in dysfibrinogenemias, with the Arg being mutated to Cys (15 families), His (10 families) or Ser [9] . Besides the γArg275 mutations, 8 variants have been reported in the D:D interface and the neighboring region between γGly268 and γMet310. We have already analyzed the fibrin polymerization of a heterozygous plasma variant fibrinogen (γArg275Cys: Matsumoto III; M-III) [10] and compared it with those occurring in heterozygous γAsp364His (Matsumoto I) [11] and γAsn308Lys (Matsumoto II) [12] . These results indicated that fibrin polymerization decreased in the order γAsn308Lys > γArg275Cys > γAsp364His, all three being decreased by comparison with normal fibrinogen. These substitutions, like most dysfibrinogens, occurred in individuals who are heterozygous for the mutation. This complicates functional analysis because fibrinogen in these individuals is a mix of normal and abnormal molecules [13, 14] . We resolved this complication by synthesizing recombinant variant fibrinogen, and we examined the changes in function associated with the change in primary structure.
Here, we describe an analysis of a heterozygous plasma variant fibrinogen (M-III) and of recombinant variant fibrinogen γ275Cys, analogous to the dysfibrinogen. On the basis of our data, substitution of γ-chain residue Arg275 by Cys results in the presence of a disulfide-linked Cys and a disruption of the initial alignment of fibrin monomers into protofibrils, these changes would appear to lead to an impairment of the subsequent factor XIIIa-catalyzed γ-γ dimer formation. The impairments in recombinant γ275C fibrinogen were markedly more pronounced than those in the heterozygous plasma fibrinogen.
Materials and Methods
Preparation of plasma and recombinant variant fibrinogen. Preparation of recombinant variant fibrinogen was performed as described before [15] . To change γ275Arg to Cys, the fibrinogen γ-chain expression vector, pMLP-γ, was altered by oligonucleotide-directed mutagenesis using the selection primer 5'-TCTAGGGCCCAGGCTTGTTTGC and the mutagenesis primer 5'-TGACAAGTACTGCCTAACATA (the altered base is underlined). The expression plasmid was cotransfected with a histidinol selection plasmid (pMSVhis) into Chinese hamster ovary (CHO) cells expressing normal human fibrinogen Aα-and Bβ-chains.
A selected and cloned colony was cultured in serum-free medium using 850 cm 2 rollerbottles coated with microbeads. Fibrinogen was purified from plasma or from harvested culture medium by immunoaffinity chromatography utilizing a calciumdependent monoclonal antibody (IF-1; Iatron Laboratories, Tokyo) [16] . The fibrinogen concentration was determined from the A 280 value, assuming that a 1 mg/ml solution has an absorbance of 1.51 [17] . The purity and characterization of the proteins was determined by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) run under either non-reducing (5% polyacrylamide gel) or reducing conditions (10% polyacrylamide gel) conditions.
Mass spectrometric analysis. Preparation of fibrinogen fragments for mass spectrometric analysis was performed as described before [18] , with a minor modification. Briefly, fibrinogen (1.3 mg) was dissolved in 300µl of 6 M guanidine hydrochloride, pH 8.5, containing 10 µL 4-vinylpyridine to derivatize free sulfhydryl groups. After 30 min, protein was precipitated using 10 vol methanol. The dried precipitate was dissolved in 300 µl of concentrated formic acid containing 30 mg cyanogen bromide, incubated for 2 h at room temperature, and the digest was fractionated into 100 tubes at 2.5 mL each on a 1.6 x 100 cm of Sephadex G-50sf column in 0.2% trifluoroacetic acid. After all fractions had been monitored at 215 nm, and concentrated, they were followed by mass spectrometric analysis in a matrixassisted laser desorption/ionization time-of-flight (MALDI-TOF) mass Voyager DE STR instrument (PE Applied Biosystems, Foster City, CA). Part of each sample was subsequently incubated overnight with mercaptoethanol (5% final concentration) at 37˚C to cleave any disulfide bonds that might be present. For all mass spectrometric analyses, 5mg/ml α-cyano-4-hydroxycinnamic acid and 0.1% trifluoroacetic acid in 37.5 % acetonitril was used as matrix.
Thrombin-catalyzed fibrin polymerization. Polymerization was followed by monitoring turbidity at 350 nm using a UV-110-02 spectrophotometer (Shimadzu Corp., Tokyo, Japan). Reactions were performed in a final volume of 100 µl, as described elsewhere [15] . Briefly, fibrinogen (90 µl at 0.1 or 0.5 mg/ml) in 20 mM N- [2-hydroxyethyl] piperazine-N'-[2-ethanesulfonic acid] (HEPES), pH 7.4, 0.12 M NaCl, with added CaCl 2 was mixed with human α-thrombin (Enzyme Research Laboratories, South
Bend, IN) (10 µl at 0.5 unit/ml), and changes in turbidity were monitored at the ambient temperature. Three parameters (lag period, maximum slope, and ∆absorbance in 30 min) were obtained from the turbidity curves, as described elsewhere [19] . The reactions were performed in triplicate for each sample. 
Scanning Electron Microscopy (SEM).
The SEM preparation was performed as described before [20] , with a few minor modifications. Briefly, 10 µl of thrombin was added to 40µl of fibrinogen solution and mixed by repeated pipetting. Polymerization then proceeded in a moisture chamber in a 37˚C incubator for 3 h. The final concentrations of fibrinogen and thrombin were 0.40 mg/ml and 0.1 unit/ml, respectively. The clots were fixed in 2.5% glutaraldehyde overnight, stained with 1% osmium tetroxide, critical-point dried, mounted, osmium plasma-coated at 5-nm thickness in an NL-OPC40 (Nippon Laser and Electronics Lab, Nagoya, Japan), and finally viewed on a JSM-6000F (Japan Electron Optics Laboratory Co. Ltd.). Images were taken at 3000x or 20000x using a 15.0 kV accelerating voltage. Fiber diameters were measured using a vernier caliper on a 300% enlargement from a photograph of a 20000x observation.
Results

Characterization of Plasma and Recombinant Fibrinogens.
We synthesized a recombinant variant fibrinogen with a single-amino acid substitution, γ275Cys (γ275C). Wild-type recombinant fibrinogen γ275Arg (γ275R) was also produced [15] and used as the normal control. When SDS-PAGE was run under non-reducing conditions with Coomassie staining, the fibrinogens purified from plasma and cultured media were pure, and the propositus and recombinant variant fibrinogens had the normal Aα  Bβ and γ-chain components ( Figure 1A ). Gel resolved under non-reducing conditions revealed that each of the four fibrinogens had two broad bands corresponding to high molecular-weight and low molecular-weight fractions [21] ( Figure 1B ). These results demonstrated that the free sulfhydryl group in the newly substituted Cys did not form significant disulfide bonds with large molecules such as albumin and/or another variant fibrinogen, which lead to a markedly increased mobility shift in SDS-PAGE.
Mass spectrometric analysis.
To identify the modifications associated with the neo-Cys residue, peptides isolated from fibrinogens were analyzed by mass spectrometry. After protecting the free sulfhydryl, if present, by vinylpyridine treatment, fibrinogen was cleaved with CNBr and the products separated on Sephadex G-50sf. To identify the relevant CNBr peptides, γ265Phe-310Met residues, dimeric molecules of variant γ265Phe-310Met
residues, and modified peptides, all gel-filtrated fractions were analyzed by mass spectrometry. The analyzed data are summarized in Table 1 .
Analysis of the M-III fibrinogen fragment revealed a normal peak, mass 5002.0, consistent with the presence of normal fragment, and an additional peak, mass 5067.9, corresponding to a variant fragment with a disulfide-linked Cys residue. 
Thrombin-catalyzed Fibrin Polymerization.
Thrombin-catalyzed fibrin polymerization (TCFP) was monitored as the change in turbidity at 350 nm, as described in Materials and Methods. Representative turbidity curves are shown in Figure 2 . We found that polymerizations of M-III and γ275C
fibrinogen were impaired relative to that of normal fibrinogen. Briefly, when 0.09 mg/ml fibrinogen was used γ275C did not polymerize for 6 h, but the curve for M-III showed increased turbidity after a longer lag period (more than 5 min) and with a slower rate of rise than the normal control (NC), and at 10 min the turbidity was greater for M-III than for NC. When a higher concentration of fibrinogen was used (0.45 mg/ml), M-III and γ275C started polymerization after lag periods of 6 and 12 min, respectively, and the M-III turbidity curve crossed those for NC at 10 min, while the γ275C curve crossed that for γ275R at 30 min. These aberrant TCFP patterns for M-III and γ275C fibrinogen were similar to those reported for Matsumoto II [10] and recombinant γ308K fibrinogen [manuscript submitted].
FXIIIa-catalyzed cross-linking of fibrin or fibrinogen.
Cross-linking of fibrin α-and γ-chains was performed in the presence of factor XIII and thrombin, and the reaction products were analyzed by SDS-PAGE, as described in Materials and Methods. After a 1-min reaction with NC fibrinogen, the γ-γ dimer band was weakly evident, and after 5 min two α-polymer bands were evident ( Figure 3A ; NC). During longer incubation periods (from 1 to 20 min), these products increased with time, while the α-and γ-chain monomer bands decreased. Formation of γ-γ dimer and α-polymer from γ275R fibrinogen was almost the same as for NC ( Figure 3A ; γ275R). For M-III fibrinogen, the γ-γ dimer and α-polymer bands were evident after 1 and 20 min, respectively ( Figure 3A ; M-III). In contrast, for γ275C fibrinogen the γ-γ dimer was evident after 20 min, while α-polymer bands were not evident for 60 min ( Figure 3A; γ275C) . To confirm the role of D:D interactions in polymerization and to assess the influence of the substitution per se, we examined the FXIIIa-catalyzed cross-linking of fibrinogen. After FXIII had been activated with thrombin, hirudin was added to inhibit thrombin-catalyzed fibrinopeptide release and fibrin polymerization, and then the enzyme mixture was added to fibrinogen solution.
After a 0.5 h reaction, the γ γ dimer and α-polymers were seen for both NC and M-III fibrinogen ( Figure 3B ; NC and M-III). In the case of γ275R fibrinogen ( Figure 3B; γ275R), again the γ-γ dimer formation started at 0.5 h, but formation of α-polymers was slightly delayed starting at 1 h. In contrast, for γ275C fibrinogen neither the γ-γ dimer nor α-polymers were evident for 24 h (Figure 3B; γ275C) . We conclude that the delay in γ-γ dimer formation between fibrin monomers that we observed with the variant fibrinogen was due to impaired alignment of the fibrin monomers.
Scanning Electron Microscopy (SEM) of Fibrin Clots and Fibers.
To clarify the difference in the ultrastructure of the fibrin clot between variant and normal fibrinogens, we observed fibrin clots under the SEM. The clots prepared from M-III fibrinogen with the aid of thrombin differed in ultrastructure from those prepared from NC fibrinogen, the density of the bundles of fibrin fibers being less in the former than in the latter case ( Figures 4A and B) and the fiber diameter being larger in the former (158 ± 55 nm) than in the latter (134 ± 30 nm) ( Figure 4B ). In addition, fibrin bundles derived from M-III fibrinogen appeared "frayed" around the major fiber in these clots and there was a marked increase in the number of fibers with abrupt terminations (by comparison with NC fibrin architecture) ( Figure 4B ). The clots prepared from γ275C fibrinogen with the aid of thrombin differed markedly in ultrastructure from those prepared from γ275R fibrinogen: viz. in the former, there were many aberrant fibrin fibers with tapered ends and the fiber diameter was much larger (366 ± 69 nm) than in the case of γ275R (142 ± 28 nm) ( Figure 4B ).
Discussion
Our results indicate that the substitution of the γ-chain residue Arg275 by Cys results in the presence of a disulfide-linked Cys and a disruption of the initial alignment of fibrin monomers into protofibrils, and that these changes lead to an impairment of the subsequent FXIIIa-catalyzed γ-γ dimer formation. Since the plasma fibrinogen purified from the heterozygous proband with dysfibrinogenemia generally contains three types of molecules (normal homodimer, variant homodimer, and heterodimer) and the expected distribution of these three molecules is 1:1:2 according to Mendelian genetics [13, 14] without unique dysfibrinogens such as Aα16Arg->Cys [22] as Bβ14Arg->Cys [23] etc, we can not know the precise function of a fibrinogen consisting only of a variant γ-chain and resulting in fibrin clot structures. To address this problem, we synthesized recombinant γ275C fibrinogen using CHO cells and compared it with heterozygous M-III plasma fibrinogen.
Because the post-translational nature of neo-Cys residues in abnormal fibrinogens is variable, we examined the nature of this neo-Cys by SDS-PAGE analysis under nonreducing conditions and by mass spectrometric analysis. The former revealed that the neo-Cys residue was not disulfide-bridged to other mobility-shifting proteins, such as albumin. Mass analysis of CNBr-cleaved fibrinogen M-III and CNBr-cleaved recombinant γ275C demonstrated that in these, this neo-Cys residue was entirely disulfide-bridged to a free Cys. Previously, neo-Cys residues in abnormal fibrinogens have been found either as free sulfhydryls or disulfide-bridged to other molecules such as albumin, Cys, or a second abnormal fibrinogen molecule [18] . In the γ-chain residue of γTyr280Cys (Banks Peninsula) [24] and in that of γSer358Cys (Milano VII) [25] , the neo-Cys residue exists as a free sulfhydryl and disulfide-bridged to albumin, respectively. In the case of γArg275Cys, only dysfibrinogen Osaka II [26] out of 12 families [9] has been demonstrated by mass analysis to possess a disulfide-bridging Cys residue. Unfortunately, we have no convincing explanation for the variability in the post-translational nature of the neo-Cys residues in abnormal fibrinogens.
Here, we found that the thrombin-catalyzed fibrin polymerization curve obtained using a high concentration of M-III or recombinant γ275C fibrinogen was unusual, each curve having a prolonged lag period and a slow rate of rise, but with a ∆absorbance in 30 min that was larger than (M-III) or almost same as (γ275C) that for NC. As we anticipated, the impairment was much more pronounced for recombinant γ275C fibrinogen than for heterozygous plasma fibrinogen from the M-III proband.
These results indicate the M-III plasma fibrinogen contains heterodimers and that after thrombin stimulation, these can polymerize with both the normal homodimers and the variant homodimers. We have previously observed similar polymerization curves for fibrinogen Matsumoto II [10] and recombinant γ308Lys [manuscript submitted], but not for either fibrinogen Matsumoto I [11] or Kosai/Ogasa (BβGly15Cys) [20] . These [29] . The above also demonstrates that γArg275 is one of the most important residues in the D:D interface.
Our scanning electron microscopic observations of fibrin clots made from recombinant γ275C revealed an extensively branched fiber network and a lower fiber density than in the case of γ275R, and the fiber bundle was 2.6 times thicker than for γ275R, although many fibers had tapered ends. Weisel and Nagaswami [30] analyzed the effects of thrombin concentration on clot structure and turbidity curves. They showed that with smaller amounts of thrombin, increasing the thrombin concentration led to decreases in average fiber-bundle size, lag period, and maximum final turbidity, while the maximum rate of turbidity development increased. These differences in clot structure and turbidity curves between higher and lower concentration of thrombin are consistent with our observations for γ275R and γ275C fibrinogens. In addition, our SEM images of fibrin clots and bundles made from γ275C fibrinogen were similar to the images of those made from fibrinogen Tokyo II observed by Mosesson et al [5] .
However, our images of fibrin clots and bundles made from M-III fibrinogen somewhat differed from those from fibrinogen Tokyo II. Namely, the number of fibrin bundles with abnormal ends in M-III fibrin clots was less than those from fibrinogen Tokyo II. These discrepancies might have been caused by the procedures used in sample preparation for SEM observation. Although we can not explain how a markedly affected D:D interaction in γ275C might lead to thicker fiber bundles, at least the D:D interface and γArg275 appear not to be essential for lateral aggregation during normal fibrin polymerization. Actually, previous X-ray crystallographic analysis has predicted that lateral aggregation takes place between the γ -chain of neighboring molecules (γ350-360 and γ370-380), and also between the β -chain of neighboring molecules (β330-375) [31] .
In conclusion, in fibrinogen the substitution of γ-chain residue Arg275 by Cys results in the presence of a disulfide-linked Cys and a disruption of the initial alignment of fibrin monomers into protofibrils, and these changes lead to an impairment of the subsequent FXIIIa-catalyzed γ-γ dimer formation. The impairment or abnormality was much more pronounced for recombinant γ275C fibrinogen than for heterozygous plasma fibrinogen. These results indicate that γArg275 has an important residue affecting the structure and function of the γ-chain C-terminal domain. However, the variant D:D interface can interact with that of the normal fibrinogen present in the plasma of a proband with heterozygous dysfibrinogenemia. 
